|1.||Hsu, Ann: 7 articles (04/2015 - 07/2009)|
|2.||Gupta, Suneel: 5 articles (04/2015 - 04/2013)|
|3.||Hauser, Robert A: 5 articles (02/2014 - 03/2009)|
|4.||Kell, Sherron: 4 articles (04/2015 - 04/2013)|
|5.||Fahn, Stanley: 3 articles (05/2015 - 12/2004)|
|6.||Pahwa, Rajesh: 3 articles (08/2014 - 03/2006)|
|7.||Lyons, Kelly E: 3 articles (08/2014 - 03/2006)|
|8.||Khanna, Sarita: 2 articles (04/2015 - 12/2014)|
|9.||Chang, Min Cheol: 2 articles (03/2015 - 03/2015)|
|10.||Stocchi, Fabrizio: 2 articles (12/2014 - 09/2010)|
|1.||Parkinson Disease (Parkinson's Disease)
11/01/1989 - "Thus, Sinemet CR seems to be beneficial and useful in the treatment of early Parkinson's disease."
11/01/1989 - "The efficacy of controlled-release Sinemet was evaluated in a 52-week open trial involving 20 patients (14 men, 6 women; mean age 66 years, range 56 to 82) with idiopathic Parkinson's disease of 8 years' mean duration. "
11/01/1989 - "Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease."
11/01/1989 - "Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease."
01/01/1989 - "Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease."
|2.||Parkinsonian Disorders (Parkinsonism)
05/01/2013 - "The parkinsonian syndromes were relieved after the administration of sinemet. "
10/30/1991 - "This paper describes a Norwegian multi-centre study of Sinemet CR in 56 patients with mild to moderate parkinsonism. "
12/01/2004 - "The patient with disabling parkinsonism was responsive to carbidopa/levodopa. "
03/01/2002 - "Carbidopa-levodopa was associated with early improvement, but discontinuation did not result in worsening of the parkinsonism."
09/26/2000 - "To describe the clinical and molecular genetic analysis of a large family of northern Chinese descent with a mutation at the SCA2 locus causing carbidopa-levodopa-responsive parkinsonism. "
08/06/1986 - "Both drugs relieved the parkinsonian symptoms but the animals on Sinemet developed after 2 weeks prominent lingual dyskinesia which remained visible after each dose until the end of the experiment. "
11/01/2015 - "Parkinson's motor complications include wearing-off, a delayed or absent response to carbidopa/levodopa therapy, freezing of gait, dyskinesias, and dystonias. "
03/01/1999 - "Patients with complex fluctuations and diphasic dyskinesias were excluded and the conversion was made after some recommendations, depending on the clinical problems and the daily dosage and administration schedule of standard (STD) Sinemet. "
05/01/1997 - "Stereotypies/dyskinesias were also quantified after high doses of oral sinemet (36 and 50 mg/kg). "
01/01/1996 - "The range of effective doses, from the minimum dose that produces beneficial effects to the dose that produces intolerable dyskinesias, is referred to as the "therapeutic window." It would be extremely valuable to assess, preclinically, the effects of novel treatments on the therapeutic window for Sinemet. "
03/01/2015 - "With a dose of 300/1200 mg/day carbidopa/levodopa, the rigidity of both upper and lower extremities was significantly reduced, and the tremor completely disappeared. "
11/01/1991 - "All patients had been or were being treated with carbidopa/levodopa but with unsatisfactory tremor control. "
08/01/1989 - "Carbidopa/levodopa reduced testing tremor in 58% and postural tremor in 46% of patients. "
02/01/1986 - "Trihexiphenidyl and carbidopa-levodopa decreased tremor by greater than 50%. "
01/01/2015 - "Improvement of Primary Writing Tremor in Parkinson's Disease with Carbidopa/Levodopa."
04/01/2013 - "In the maintenance period, the most common adverse events were insomnia (seven [3%] of 201 patients allocated extended-release carbidopa-levodopa vs two [1%] of 192 patients allocated immediate-release carbidopa-levodopa), nausea (six [3%] vs three [2%]), and falls (six [3%] vs four [2%]). "
09/01/1997 - "The combination of tolcapone and carbidopa-levodopa was generally well tolerated, although more nausea and vomiting were observed at higher dosages (400 to 800 mg t.i.d.), particularly in women. "
03/01/1978 - "Almost all patients showed great reduction in nausea and vomiting with both Madopa and Sinemet. "
02/01/1988 - "Adverse effects included nausea, light-headedness, dyskinesias, and hallucinations, all of which abated after the Sinemet dose was reduced. "
01/01/1992 - "A more efficient inhibition of dopamine formation from levodopa (resulting in higher 3-OMD levels) by Madopar HBS was consistent with the superior tolerability (especially for initial nausea) observed for the Madopar HBS formulation as compared to Sinemet CR."
|1.||levodopa drug combination carbidopa (Nakom)
|2.||Levodopa (L Dopa)
|4.||levodopa drug combination benserazide
|8.||Dopamine Agonists (Dopamine Agonist)
|2.||Investigational Therapies (Experimental Therapy)
|3.||Ambulatory Surgical Procedures (Outpatient Surgery)
|4.||Drug Therapy (Chemotherapy)
|5.||Psychology Biofeedback (Biofeedback)